文献速递类风湿关节炎

ACPA阳性早期类风湿关节炎患者实现临床缓解的预测因素:AVERT与AVERT-II试验事后分析

Predictors of achieving clinical remission in ACPA-positive RA-patients treated with abatacept and methotrexate and methotrexate monotherapy: a post-hoc analysis of the AVERT and AVERT-II trials.
PubMed 文献 · Semin Arthritis Rheum · 2026-01-12

该研究基于AVERT和AVERT-II随机对照试验的事后分析,纳入ACPA阳性早期类风湿关节炎患者,分别接受甲氨蝶呤单药或阿巴西普联合甲氨蝶呤治疗,构建逻辑回归模型预测6个月和12个月DAS28-CRP缓解。结果显示基线DAS28-CRP和早期DAS28应答是唯一一致的预测因素,而基线血清学、影像学或HLA共享表位等参数未显著改善模型性能。

要点

  • 甲氨蝶呤单药组6个月和12个月DAS28缓解率分别为27%和39%,联合治疗组分别为43%和53%。
  • 基线DAS28-CRP在所有模型中均预测临床缓解,早期DAS28应答可改善模型性能。
  • 基线MRI关节炎症、血清学或HLA共享表位未显著改善模型性能。

核心结论

  • 判断哪些患者经甲氨蝶呤或阿巴西普联合甲氨蝶呤治疗可实现临床缓解仍具挑战性。
  • 疾病初诊时的疾病活动和早期DAS应答是达到临床缓解的唯一一致预测因素。
  • 遗传、影像学和血清学参数未改善模型性能。

研究设计与样本

  • AVERT和AVERT-II随机对照试验的事后分析,纳入ACPA阳性早期RA患者,接受甲氨蝶呤单药或阿巴西普联合甲氨蝶呤治疗。
  • 甲氨蝶呤单药组388例,阿巴西普联合甲氨蝶呤组743例。
  • 在观察性Leiden早期关节炎门诊队列中对甲氨蝶呤单药患者进行外部模型验证。
  • 主要结局为6个月和12个月随访时的DAS28-CRP缓解。
  • 使用逻辑回归分析构建预测模型,先纳入仅临床基线变量,再评估加入血清学、影像学、共享表位或早期DAS28应答是否改善模型性能。

主要发现

  • 甲氨蝶呤单药组6个月和12个月DAS28缓解率分别为27%和39%;阿巴西普联合甲氨蝶呤组分别为43%和53%。
  • 基线DAS28-CRP在所有模型中均预测临床缓解。
  • 6个月和12个月DAS28缓解的乐观校正模型性能(AUROC)在甲氨蝶呤组为0.66/0.65,在阿巴西普联合甲氨蝶呤组为0.68/0.59。
  • 加入基线MRI检测的关节炎症、基线血清学或HLA共享表位等位基因未显著改善模型性能。
  • 早期DAS28应答确实改善了模型性能;外部验证队列中模型性能非常相似。

关键数值与推荐

  • 甲氨蝶呤单药组(n=388)6个月和12个月DAS28缓解率分别为27%和39%。
  • 阿巴西普联合甲氨蝶呤组(n=743)6个月和12个月DAS28缓解率分别为43%和53%。
  • 6个月和12个月DAS28缓解的AUROC在甲氨蝶呤组为0.66/0.65,在阿巴西普联合甲氨蝶呤组为0.68/0.59。

临床怎么用

  • 对于ACPA阳性早期RA患者,基线疾病活动度(DAS28-CRP)和早期DAS28应答可用于辅助预测甲氨蝶呤单药或阿巴西普联合甲氨蝶呤治疗的临床缓解可能性。
  • 基线血清学、影像学或HLA共享表位等参数在预测临床缓解方面未显示额外价值,不建议常规用于此目的。

局限性

  • 本研究为AVERT和AVERT-II试验的事后分析,预测模型性能仅为中等(AUROC 0.59-0.68),临床实用性有限。
  • 外部验证仅在甲氨蝶呤单药治疗的观察性Leiden早期关节炎门诊队列中进行,未在阿巴西普联合甲氨蝶呤治疗患者中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To predict which early RA-patients achieve clinical remission on initial treatment with methotrexate monotherapy or with abatacept+methotrexate. METHODS: This study is a subanalysis of the AVERT and AVERT-2 randomized controlled trials, which were performed in ACPA-positive early RA-patients who received methotrexate monotherapy or abatacept + methotrexate. External model validation of patients on methotrexate monotherapy was performed in the observational Leiden Early Arthritis Clinic (EAC) cohort. Primary outcome was DAS28-CRP remission at 6 and 12 months follow-up. Prediction models were developed using logistic regression analysis. First, a model including clinical baseline variables only was estimated. Subsequently, it was assessed whether adding serological or imaging data, shared epitope or early DAS28 response improved model performance. RESULTS: In the methotrexate-monotherapy group (n=388), 27% and 39% of patients achieved DAS28-remission after 6 and 12-months. In the abatacept + methotrexate group (n=743) this was 43% and 53%. Baseline DAS28-CRP was predictive for clinical remission in all models. Optimism-adjusted model performance (AUROC) for DAS28-remission at 6 and 12-months was 0.66/0.65 in the methotrexate-group and 0.68/0.59 in the abatacept + methotrexate group. Adding baseline MRI-detected joint-inflammation, baseline serology or HLA-shared epitope alleles did not significantly improve model performance. Early DAS28-response did improve model performance. In the external validation cohort model performance was very similar. CONCLUSION: Determining which patients achieve clinical remission upon methotrexate or abatacept+methotrexate treatment remains challenging. Disease activity at disease presentation and early DAS response were the only consistent predictors for achieving clinical remission. Genetic, imaging and serology parameters did not improve model performance.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Bergstra SA, Verstappen M, Niemantsverdriet E, et al. Predictors of achieving clinical remission in ACPA-positive RA-patients treated with abatacept and methotrexate and methotrexate monotherapy: a post-hoc analysis of the AVERT and AVERT-II trials. Semin Arthritis Rheum. 2026. PMID: 41544399. doi:10.1016/j.semarthrit.2026.152917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。